PASSReviewer 1· 95% conf
The trial design is rigorous: randomized, double-blind, placebo-controlled, with a pre-specified sample size and analysis plan.
Evidence
direct quote[Methods, Intervention: Randomization and Blinding]
“Randomization occurred immediately before surgery in a 1:1 ratio. Treatment assignments were concealed from study participants and personnel, except for investigators responsible for shunt adjustments, and were disclosed only for patient safety reasons.”direct quote[Methods, Statistical Analysis]
“A sample size of 100 participants was specified, providing >90% power to detect a between group gait velocity difference of 0.2 m/s (SD=0.29 m/s), accounting for interim analyses and attrition.”direct quote[Methods, Participants]
“Following the International iNPH Guidelines, patients selected for VP shunt surgery based on their gait velocity response to temporary CSF drainage were eligible. At baseline, patients who could not walk 10 meters or who required assistance from a person to walk were excluded, as were those with gait velocity ≥1.0 m/sec unless velocity improved ≥30% with CSF drainage.”PASSReviewer 2· 95% conf
The study design is rigorous, with clear randomization, blinding, a pre-specified power analysis, and defined inclusion/exclusion criteria.
Evidence
paraphrase[Methods, Randomization and Blinding]
“Randomization occurred immediately before surgery in a 1:1 ratio. Treatment assignments were concealed from study participants and personnel, except for investigators responsible for shunt adjustments.”paraphrase[Methods, Statistical Analysis]
“A sample size of 100 participants was specified, providing >90% power to detect a between group gait velocity difference of 0.2 m/s (SD=0.29 m/s).”direct quote[Methods, Participants]
“At baseline, patients who could not walk 10 meters or who required assistance from a person to walk were excluded, as were those with gait velocity ≥1.0 m/sec unless velocity improved ≥30% with CSF drainage.”